VERAXA Biotech AG (NASDAQ: VRXA) has announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program, selecting ATUM, a U.S.-based contract research organization, to support manufacturing development as the candidate advances toward IND/CTA-enabling studies. The collaboration represents an important development milestone, supporting manufacturing, analytical development, and nonclinical studies required before clinical testing.
ATUM will apply its proprietary Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA's lead therapeutic candidate. This technology is designed to improve the efficiency and stability of cell line generation, which is critical for producing consistent and high-quality biologics for clinical trials. The partnership underscores VERAXA's commitment to advancing its pipeline of novel cancer therapies.
VERAXA's BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. By engaging T cells more precisely against tumor cells, the platform aims to enhance therapeutic efficacy while minimizing off-target effects. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.
The selection of ATUM for cell line development is a key step in preparing the company's most advanced oncology candidate for future clinical development. According to VERAXA, the collaboration is intended to leverage ATUM's expertise in bioengineering and cell line development to accelerate the timeline toward regulatory filings. The company's lead BiTAC-TCE program targets a solid tumor indication, though specific details have not been disclosed.
VERAXA Biotech is an emerging leader in designing novel cancer therapies, with a focus on T-cell engagers and other immunotherapeutic approaches. The company's pipeline includes multiple programs in preclinical development, with the lead candidate now advancing toward the clinic. The cell line development partnership with ATUM is expected to support the manufacturing, analytical development, and nonclinical studies required to file an Investigational New Drug (IND) application or Clinical Trial Application (CTA).
For more information on VERAXA Biotech, visit the company's newsroom at https://ibn.fm/VRXA. This development highlights the progress being made in the field of targeted cancer therapies and the potential of BiTAC technology to improve patient outcomes.
